Hematology
Refine Search
Biotechnology
Japanese drug major Takeda today revealed that the Phase III PhALLCON trial of Iclusig (ponatinib) for adult patients with newly-diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) met its primary efficacy endpoint in the frontline setting. 17 November 2022
Pharmaceutical
Notable research news last week included UK pharma major GSK releasing disappointing Phase III trial results for its already approved multiple myeloma drug Blenrep. Also, French drugmaker Ipsen presented positive new Phase III data on its Onivyde in pancreatic cancer. M&A developments saw significant change of focus for generic drugmaker Viatris, which plans to establish an ophthalmic franchise through the acquisition of Oyster Point Pharma and Famy Life Sciences for around $700-$750 million. Also of note, France’s Sanofi entered into an agreement with artificial intelligence (AI) firm Insilico Medicines, potentially worth $1.2 billion to the latter. 13 November 2022
Biotechnology
Shares of USA-based Kronos Bio plunged more than 9% to $2.32 in early trading today, after it announced the prioritization of its clinical portfolio to focus on the development of its next generation SYK inhibitor, lanraplenib, and its CDK9 inhibitor, KB-0742. 10 November 2022
Biotechnology
The entry of new treatments for atypical hemolytic uremic syndrome (aHUS) such as Swiss pharmaceutical giants Novartis and Roche that have strong digital experience can alter the aHUS digital landscape dynamics in Japan, says data and analytics company GlobalData. 10 November 2022
Biotechnology
Shares of Sino-American biotech BeiGene rose as much as 3.8% to 133.97 renminbi when trading started this morning, as the company released third-quarter 2022 financial results that beat consensus forecasts. 10 November 2022
Biotechnology
UK pharma major GSK’s shares were down 4.3% at 1,383.60 pence by early afternoon today, as it announced disappointing Phase III results with its Blenrep (belantamab mafodotin). 7 November 2022
Biotechnology
Featured research news last week included US pharma major Bristol Myers Squibb releasing top-line results from a Phase III study suggesting its Reblozyl can address a wider myelodysplastic syndrome patient group. Actinium Pharmaceuticals reported positive top-line Phase III results for it acute myeloid leukemia (AML) candidate Iomab-B. Also, US pharma giant Pfizer last Tuesday presented strong data for its RSVpreF respiratory syncytial virus (RSV) vaccine program. On the deal-making front, US MRNA technology company Arcturus Therapeutics hit the jackpot last week, inking a potentially hugely lucrative deal with Australian biotech CSL Limited, to access the firm’s late-stage self-amplifying mRNA (sa-mRNA) vaccine platform technology. 6 November 2022
Biotechnology
Germany’s Affimed saw its shares leap more than 17% to $1.98 today, after it revealed a collaboration with privately held US biotech Artiva Biotherapeutics. 3 November 2022
Biotechnology
Australia’s CSL Limited has sought to shed light on the promise of its pipeline at its annual R&D investor briefing. 3 November 2022
Biotechnology
Boston, USA-based pricing watchdog The Institute for Clinical and Economic Review (ICER) has published an evidence report on the comparative clinical effectiveness of hemophilia treatments. 2 November 2022
Biosimilars
Four years after it was established, Syna Therapeutics has just signed an exclusive license agreement with Indian drugmaker Intas Pharmaceuticals and its wholly-owned subsidiary Accord Healthcare for the marketing worldwide of its biosimilar medicine LB-0702 to treat pathologies in the field of hematology. 2 November 2022
Biotechnology
Switzerland-headquartered antibody-drug conjugate specialist ADC Therapeutics today announced the appointment of Kristen Harrington-Smith as chief commercial officer, effective November 17, 2022, and Peter Graham as chief legal officer, effective today. 1 November 2022
Biotechnology
Having soared as much as 164% earlier in the day, shares of USA-based Coeptis Therapeutics closed down 45% at $6.50 on the Nasdaq, after it announced the completion of its business combination with Bull Horn Holdings, a special purpose acquisition company (SPAC). 1 November 2022
Pharmaceutical
Targeted radiotherapy firm Actinium Pharmaceuticals has announced positive top-line results from the Phase III SIERRA study. 31 October 2022
Biotechnology
New top-line data released this morning by US pharma major Bristol Myers Squibb suggest that its already-marketed drug Reblozyl (luspatercept-aamt) should be able to address a larger proportion of myelodysplastic syndromes (MDS) patients. 31 October 2022
Biotechnology
Sino-American biotech BeiGene claims significant progress in its efforts to unlock global opportunities for its Brukinsa (zanubrutinib) with recent regulatory approvals in six Latin American countries. 31 October 2022
Biotechnology
Among significant research news last week, Swiss pharma giant Novartis announced Phase III results for its investigational drug iptacopan, demonstrating superiority to AstraZeneca’s blockbuster franchise – Solaris and Ultomiris - in the treatment of hemoglobinuria (PNH). Mirum Pharmaceuticals released new Phase III data on Livmarli, a proposed treatment for the rare pediatric disease familial intrahepatic cholestasis (PFIC). And UK pharma major GSK last Thursday revealed it is discontinuing development of the investigational drug otilimab in rheumatoid arthritis. Also of note, Johnson & Johnson’s Janssen unit last Tuesday received a second approval for its multiple myeloma drug Tecvayli, this time from the US Food and Drug Administration (FDA). 30 October 2022
Pharmaceutical
US pharma major AbbVie saw its shares decline 4.5% to $146.77 by mid-morning today, after it reported third-quarter 2022 financials that beat analysts’ forecasts on earnings but fell short on revenue expectations. 28 October 2022
article
Chief executive Paul Hudson presented an upbeat results statement for Sanofi Friday morning, highlighting strong performance in the third quarter and a range of clinical developments under way. 28 October 2022
Biotechnology
Gilead Sciences announced its financial results for the third quarter of 2022 after markets closed yesterday, but the US biotech major’s shares were up 4.8% at $73.58 pre-market today. 28 October 2022
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Biotechnology
The European Commission (EC) has granted marketing authorization for Hympavzi (marstacimab), from US pharma giant Pfizer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals’ Revuforj (revumenib). 18 November 2024
Biotechnology
UK drugmaker GSK might be trading lower following Thursday’s nomination of vaccine sceptic Robert F Kennedy Jr as the USA’s next health secretary, but the day brought good news for the group elsewhere in the business. 15 November 2024
Biotechnology
Adaptimmune Therapeutics reported promising data Wednesday from its pivotal Phase II trial of lete-cel in certain solid tumors with few effective treatments. 14 November 2024
Biotechnology
Sanofi has announced that the UK's health technology assessor will conduct a new review of its Sarclisa (isatuximab) combo therapy for relapsed or refractory multiple myeloma. 13 November 2024
Biotechnology
Syndax Pharmaceuticals has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib achieved its primary endpoint. 13 November 2024
Biotechnology
VarmX, a Dutch biotech developing innovative approaches for the bypass of direct oral anticoagulants targeting activated factor Xa (FXa DOACs) and inherited coagulation disorders, has appointed industry veteran John Glasspool (pictured, above) as chief executive. 12 November 2024
Biotechnology
On November 8, the US Food and Drug Administration approved Aucatzyl (obecabtagene autoleucel; obe-cel) from US biopharma Autolus Therapeutics' 11 November 2024
Biotechnology
Geron Corporation, a biopharma company focused on telomerase inhibition therapies, has announced a $375 million financing agreement aimed at supporting the commercial rollout of Rytelo (imetelstat). 11 November 2024
Biotechnology
US healthcare giant Johnson & Johnson today revealed it has submitted applications with the US Food and drug Administration (FDA) and European Medicines Agency (EMA) to expand the approved indications for its Darzalex (daratumumab) subcutaneous (SC) formulation for the treatment of high-risk smouldering multiple myeloma (SMM). 8 November 2024
Biotechnology
UK health technology assessor the National Institute for Health and Care Excellence (NICE) issued final guidance recommending reimbursement of Ayvakyt (avapritinib) from USA-based Blueprint Medicines. 6 November 2024
Biotechnology
French drugmaker Sanofi has revealed the results from the Phase III LUNA 3 trial of rilzabrutinib, an oral bruton tyrosine kinase (BTK) inhibitor, in persistent or chronic immune thrombocytopenia (ITP). 6 November 2024
Biotechnology
Beam Therapeutics will detail new clinical and preclinical data on its sickle cell disease (SCD) therapies at the upcoming American Society of Hematology (ASH) meeting. 6 November 2024
Pharmaceutical
An impressive set of quarterly financial results and an improved outlook for the rest of the year were announced by Bristol Myers Squibb on Thursday. 31 October 2024
Biotechnology
Maryland, USA–based glycobiology specialist GlycoMimetics has entered into an acquisition agreement with Crescent Biopharma, a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. 30 October 2024
Pharmaceutical
Novartis late yesterday revealed that Scemblix (asciminib) was granted accelerated approval by the US Food and Drug Administration (FDA) for adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP). 30 October 2024
Biotechnology
Last week Vertex Pharmaceuticals released positive Phase III results for its suzetrigine for moderate-to-severed pain. Belgium’s UCB revealed that Swiss pharma giant Roche was terminating its collaboration on the Alzheimer’s candidate bepranemab. The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) declined to recommend a second Alzheimer’s treatment, this time Eli Lilly’s Kisunla. Also of note, Lyell Immunopharma announced its planned acquisition of ImmPACT Bio and reprioritization of its own clinical pipeline. 27 October 2024
Biotechnology
California, USA-based Lyell Immunopharma (Nasdaq: LYEL) has entered into a definitive agreement to acquire privately-held US CAR-T company ImmPACT Bio. 26 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze